New drug duo aims to wipe out liver cancer before surgeons even operate
NCT ID NCT04721132
Summary
This study is testing whether giving two immunotherapy drugs before surgery can help people with operable liver cancer. The drugs, atezolizumab and bevacizumab, aim to help the body's immune system attack the cancer and cut off its blood supply. Researchers hope this pre-surgery treatment will kill more cancer cells and lower the chance of the cancer coming back after the operation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.